Fig. 4

Programming of LOX high expression induced by PDE in offspring rats mediated elevated ROS. A, C Representative images of LOX immunohistochemical-paraffin staining with DAPI in decalcified bone sections of fetal and adult offspring rats. B, D Quantification analyses of LOX protein mean optical density. E LOX mRNA expression in osteoclasts treated with different concentrations of DEX. F Representative images of LOX immunohistochemical-paraffin staining with DAPI in osteoclasts treated with different concentrations of DEX. G Quantification analyses of LOX protein mean optical density. H Representative images of ROS production and TRAP staining of osteoclasts in the 500 nM DEX group with or without LOX-siRNA. I Quantification analyses of ROS mean optical density. J Quantification analyses of TRAP⁺ osteoclastic cells number per well. Mean ± S.E.M., n = 6 per group for mRNA expression in vitro, n = 3 per group for LOX immunohistochemical-paraffin, ROS production, and TRAP staining. ^*P < 0.05, ^**P < 0.01 vs. Control in vivo or 0 nM DEX in vitro. ^##P < 0.01 vs. PDE in vivo or 500 nM DEX in vitro. LOX: lysyl oxidase; PDE: prenatal dexamethasone exposure; ROS: reactive oxygen species; TRAP: tartrate-resistant acid phosphatase; DEX: dexamethasone